|
gptkbp:instanceOf
|
gptkb:drug
gptkb:anticoagulant
polysaccharide
|
|
gptkbp:administeredBy
|
subcutaneous injection
intravenous injection
|
|
gptkbp:antidote
|
gptkb:protamine_sulfate
|
|
gptkbp:approvedBy
|
1930s
|
|
gptkbp:ATCCode
|
gptkb:B01AB01
|
|
gptkbp:brand
|
gptkb:Calciparine
gptkb:Hep-Lock
gptkb:Heparin_Sodium
|
|
gptkbp:CASNumber
|
9005-49-6
|
|
gptkbp:category
|
antithrombotic agent
biological product
glycosaminoglycan
|
|
gptkbp:chemicalFormula
|
variable (polysaccharide)
|
|
gptkbp:contraindication
|
active bleeding
history of heparin-induced thrombocytopenia
severe thrombocytopenia
|
|
gptkbp:discoveredBy
|
gptkb:Jay_McLean
|
|
gptkbp:discoveredIn
|
1916
|
|
gptkbp:eliminationHalfLife
|
1–2 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:foundIn
|
gptkb:mast_cells
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Heparin
|
|
gptkbp:includedIn
|
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
|
gptkbp:inhibitedBy
|
gptkb:factor_Xa
gptkb:thrombin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
activates antithrombin III
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
3,000–30,000 Da
|
|
gptkbp:notGivenBy
|
oral route
|
|
gptkbp:pregnancyCategory
|
safe in pregnancy
|
|
gptkbp:producedBy
|
bovine lung
porcine intestinal mucosa
|
|
gptkbp:riskFactor
|
gptkb:heparin-induced_thrombocytopenia
hyperkalemia
osteoporosis (long-term use)
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:heparin-induced_thrombocytopenia
bleeding
osteoporosis (with long-term use)
|
|
gptkbp:UNII
|
GGO4Y809LO
|
|
gptkbp:usedFor
|
prevention of blood clots
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
|
|
gptkbp:usedIn
|
cardiac surgery
dialysis
catheter flushes
|
|
gptkbp:bfsParent
|
gptkb:Pharmacia
|
|
gptkbp:bfsLayer
|
5
|